PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 22718316-9 2013 TPA-induced DSPC secretion and apoptosis were elevated in VEGF-deficient type II cells. Tetradecanoylphorbol Acetate 0-3 vascular endothelial growth factor A Mus musculus 58-62 25682767-2 2015 It was suggested that the interleukin-23 (IL-23)/IL-17A cytokine axis played a critical role in the pathogenesis of 12-O-tetradecanoyl phorbol 12-myristate 13-acetate (TPA)-induced K14-VEGF transgenic psoriasis-like mice model. Tetradecanoylphorbol Acetate 168-171 vascular endothelial growth factor A Mus musculus 185-189 25682767-3 2015 Here, we report that topical use of a curcumin gel formulation inhibited TPA-induced Th1 inflammation in K14-VEGF transgenic mice ears but not Th17 inflammation as expected. Tetradecanoylphorbol Acetate 73-76 vascular endothelial growth factor A Mus musculus 109-113 25682767-7 2015 In conclusion, curcumin inhibits TPA-induced Th1 inflammation in K14-VEGF transgenic mice which has not been previously described. Tetradecanoylphorbol Acetate 33-36 vascular endothelial growth factor A Mus musculus 69-73 25682767-0 2015 Curcumin relieves TPA-induced Th1 inflammation in K14-VEGF transgenic mice. Tetradecanoylphorbol Acetate 18-21 vascular endothelial growth factor A Mus musculus 54-58 18579711-5 2008 Inflammation was induced in the ear skin with five topical applications of 12-O-tetradecanoyl phorbol-13-acetate (TPA) and a significantly increased inflammation was found in TPA-induced K14/VEGF transgenic animals compared with wild-type mice. Tetradecanoylphorbol Acetate 175-178 vascular endothelial growth factor A Mus musculus 191-195 21784979-8 2011 Impaired TetON-HIF-1:VEGF(Delta) neovascularization could be partially rescued by 12-O-tetradecanoylphorbol-13-acetate skin treatment. Tetradecanoylphorbol Acetate 82-118 vascular endothelial growth factor A Mus musculus 21-25 18579711-11 2008 In conclusion, the TPA-induced phenotype in K14/VEGF animals displayed several features of psoriasis, including a T(h)17 cytokine profile and a chronic-like progression, and can be used as an in vivo screening model of psoriasis. Tetradecanoylphorbol Acetate 19-22 vascular endothelial growth factor A Mus musculus 48-52 15922088-7 2005 The VEGF synthesis stimulated by 12-O-tetradecanoylphorbol-13-acetate (TPA), a direct activator of PKC, was suppressed by tiludronate. Tetradecanoylphorbol Acetate 33-69 vascular endothelial growth factor A Mus musculus 4-8 16673205-6 2006 12-O-tetradecanoylphorbol-13-acetate (TPA), a direct activator VEGF synthesis induced by PKC, was inhibited by minodronate. Tetradecanoylphorbol Acetate 0-36 vascular endothelial growth factor A Mus musculus 63-67 16673205-6 2006 12-O-tetradecanoylphorbol-13-acetate (TPA), a direct activator VEGF synthesis induced by PKC, was inhibited by minodronate. Tetradecanoylphorbol Acetate 38-41 vascular endothelial growth factor A Mus musculus 63-67 15922088-7 2005 The VEGF synthesis stimulated by 12-O-tetradecanoylphorbol-13-acetate (TPA), a direct activator of PKC, was suppressed by tiludronate. Tetradecanoylphorbol Acetate 71-74 vascular endothelial growth factor A Mus musculus 4-8 10880381-6 2000 Topical application of 12-O-tetradecanoylphorbol-13-acetate (TPA) induced strong VEGF-GFP expression in suprabasal epidermis. Tetradecanoylphorbol Acetate 23-59 vascular endothelial growth factor A Mus musculus 81-85 11779150-5 2002 High glucose and the PKC stimulator, phorbol 12-myristate 13-acetate (PMA) induced activator protein-1 (AP-1)-dependent transcriptional activity and expression of VEGF. Tetradecanoylphorbol Acetate 37-68 vascular endothelial growth factor A Mus musculus 163-167 11779150-5 2002 High glucose and the PKC stimulator, phorbol 12-myristate 13-acetate (PMA) induced activator protein-1 (AP-1)-dependent transcriptional activity and expression of VEGF. Tetradecanoylphorbol Acetate 70-73 vascular endothelial growth factor A Mus musculus 163-167 10880381-6 2000 Topical application of 12-O-tetradecanoylphorbol-13-acetate (TPA) induced strong VEGF-GFP expression in suprabasal epidermis. Tetradecanoylphorbol Acetate 61-64 vascular endothelial growth factor A Mus musculus 81-85 9743532-3 1998 Mouse mast cells release VPF/VEGF upon stimulation through Fcepsilon receptor I (FcepsilonRI) or c-kit, or after challenge with the protein kinase C activator, phorbol myristate acetate, or the calcium ionophore, A23187; such mast cells can rapidly release VPF/VEGF, apparently from a preformed pool, and can then sustain release by secreting newly synthesized protein. Tetradecanoylphorbol Acetate 160-185 vascular endothelial growth factor A Mus musculus 257-260 10558913-6 1999 Interestingly, okadaic acid-induced upregulation of VEGF mRNA was not suppressed by protein kinase C (PKC) inhibitor or by tumor necrosis factor alpha blocking antibody, although TPA-induced VEGF upregulation was strongly suppressed by PKC inhibitor. Tetradecanoylphorbol Acetate 179-182 vascular endothelial growth factor A Mus musculus 191-195 10889466-6 2000 12-O-Tetradecanoylphorbol-13-acetate (TPA), a protein kinase C (PKC)-activating phorbol ester, stimulated VEGF secretion. Tetradecanoylphorbol Acetate 0-36 vascular endothelial growth factor A Mus musculus 106-110 10889466-6 2000 12-O-Tetradecanoylphorbol-13-acetate (TPA), a protein kinase C (PKC)-activating phorbol ester, stimulated VEGF secretion. Tetradecanoylphorbol Acetate 38-41 vascular endothelial growth factor A Mus musculus 106-110 10889466-8 2000 TPA-induced VEGF secretion was suppressed by SB203580. Tetradecanoylphorbol Acetate 0-3 vascular endothelial growth factor A Mus musculus 12-16 10617662-3 2000 Using normal human keratinocytes in conventional cultures and skin grafted onto nude mice in vivo, we show that retinoids can inhibit TPA-mediated VEGF gene induction at the transcriptional level. Tetradecanoylphorbol Acetate 134-137 vascular endothelial growth factor A Mus musculus 147-151 9743532-3 1998 Mouse mast cells release VPF/VEGF upon stimulation through Fcepsilon receptor I (FcepsilonRI) or c-kit, or after challenge with the protein kinase C activator, phorbol myristate acetate, or the calcium ionophore, A23187; such mast cells can rapidly release VPF/VEGF, apparently from a preformed pool, and can then sustain release by secreting newly synthesized protein. Tetradecanoylphorbol Acetate 160-185 vascular endothelial growth factor A Mus musculus 261-265 10091935-5 1998 TPA-treated B16F1 cells showed enhanced release of basic FGF (bFGF) and vascular endothelial growth factor (VEGF) and increased angiogenic capacity and lung colony formation in vivo. Tetradecanoylphorbol Acetate 0-3 vascular endothelial growth factor A Mus musculus 72-106 10091935-5 1998 TPA-treated B16F1 cells showed enhanced release of basic FGF (bFGF) and vascular endothelial growth factor (VEGF) and increased angiogenic capacity and lung colony formation in vivo. Tetradecanoylphorbol Acetate 0-3 vascular endothelial growth factor A Mus musculus 108-112 9704334-10 1998 Phorbol 12-myristate 13-acetate (PMA, 2 or 5 nM) protected CCE cells against apoptosis induced by the introduction of TGF-beta 1 and withdrawal of aFGF, bFGF or VEGF, while H7 (50 microM), but not HA1004 (50 microM), abrogated the protective effect of PMA on CCE apoptosis. Tetradecanoylphorbol Acetate 0-31 vascular endothelial growth factor A Mus musculus 161-165 8968091-4 1996 VEGF/VPF mRNA was induced in skin in vivo after 12-O-tetradecanoylphorbol-13-acetate treatment. Tetradecanoylphorbol Acetate 48-84 vascular endothelial growth factor A Mus musculus 0-4 9704334-10 1998 Phorbol 12-myristate 13-acetate (PMA, 2 or 5 nM) protected CCE cells against apoptosis induced by the introduction of TGF-beta 1 and withdrawal of aFGF, bFGF or VEGF, while H7 (50 microM), but not HA1004 (50 microM), abrogated the protective effect of PMA on CCE apoptosis. Tetradecanoylphorbol Acetate 33-36 vascular endothelial growth factor A Mus musculus 161-165 8968091-4 1996 VEGF/VPF mRNA was induced in skin in vivo after 12-O-tetradecanoylphorbol-13-acetate treatment. Tetradecanoylphorbol Acetate 48-84 vascular endothelial growth factor A Mus musculus 5-8 7592779-1 1995 Stimulation of NIH 3T3 cells with platelet-derived growth factor (PDGF)-BB and 12-O-tetradecanoylphorbol-13-acetate (TPA) enhances vascular endothelial growth factor (VEGF) gene expression. Tetradecanoylphorbol Acetate 117-120 vascular endothelial growth factor A Mus musculus 167-171 7592779-1 1995 Stimulation of NIH 3T3 cells with platelet-derived growth factor (PDGF)-BB and 12-O-tetradecanoylphorbol-13-acetate (TPA) enhances vascular endothelial growth factor (VEGF) gene expression. Tetradecanoylphorbol Acetate 79-115 vascular endothelial growth factor A Mus musculus 131-165 7592779-2 1995 To address the question of whether Ras and Raf are involved in the induction of VEGF gene expression by PDGF and TPA, we examined the effects of both factors on NIH 3T3 cells stably transfected with v-Ha-ras or v-raf. Tetradecanoylphorbol Acetate 113-116 vascular endothelial growth factor A Mus musculus 80-84 7592779-1 1995 Stimulation of NIH 3T3 cells with platelet-derived growth factor (PDGF)-BB and 12-O-tetradecanoylphorbol-13-acetate (TPA) enhances vascular endothelial growth factor (VEGF) gene expression. Tetradecanoylphorbol Acetate 79-115 vascular endothelial growth factor A Mus musculus 167-171 7592779-4 1995 Stimulation with PDGF or TPA resulted in increased VEGF mRNA in all cell lines, with highest levels found in the transformed cells. Tetradecanoylphorbol Acetate 25-28 vascular endothelial growth factor A Mus musculus 51-55 7592779-1 1995 Stimulation of NIH 3T3 cells with platelet-derived growth factor (PDGF)-BB and 12-O-tetradecanoylphorbol-13-acetate (TPA) enhances vascular endothelial growth factor (VEGF) gene expression. Tetradecanoylphorbol Acetate 117-120 vascular endothelial growth factor A Mus musculus 131-165